peldesine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002237)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Purine nucleoside phosphorylaseINHIBITOR
PNP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc2c(Cc3cccnc3)c[nH]c2c(=O)[nH]1- Mol. weight
- 241.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL311300 ↗
Also known as
- 2-amino-3,5-dihydro-7-(3-pyridylmethyl)-4h-pyrrolo(3,2-d)pyrimidin-4-one
- 2-amino-3,5-dihydro-7-(3-pyridylmethyl)-4h-pyrrolo(3,2-d)pyrimidin-4-one
- 4h-pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)-
- 4h-pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)-
- 9-(3-pyridylmethyl)-7h-9-deazaguanine
- bcx 34
- bcx-34
- bcx-34
- bcx-34
- peldesine
- peldesine
- peldesine
- peldesine
- peldesine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002237 | Phase 1 | Nov 2, 1999 | BioCryst |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioCryst | For profit | 1 | 1 | 1 | 1999 |
1 organizations
Page 1 / 1